Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635631 | 0.79 | PIK3CA (0.51) | — | |
| SCHEMBL2954143 | 0.76 | MAPK14 (0.60) | HTR6 | |
| Hydrochloric Acid SCHEMBL2955401 | 0.75 | MAPK14 (0.58) | HTR6 | |
| SCHEMBL1579904 | 0.74 | ALDH1A1 (0.48) | HTR6 | |
| SCHEMBL1579236 | 0.73 | TAAR1 (0.45) | HTR6 | |
| SCHEMBL12671722 | 0.72 | HTR2C (0.46) | — | |
| SCHEMBL1579976 | 0.72 | ADRB1 (0.41) | HTR6 | |
| SCHEMBL1579973 | 0.72 | ADRB1 (0.41) | HTR6 | |
| SCHEMBL30394401 | 0.72 | HTR6 (0.71) | HTR6 | |
| SCHEMBL28311460 | 0.72 | HTR6 (0.71) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102159554-B | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| EP-2310374-B1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-31 | — | — | EP | disclosed |
| CN-102159554-A | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2011-08-17 | — | — | CN | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| EP-2310374-A1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010000456-A1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | HTR6, HTR5A, HTR1A | HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.